Byung-Joo Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Byung-Joo Park has a total of 593 co-authors. Here are the top co-authors by number of shared publications:
- Nam-Kyong Choi
Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, Korea
44 shared publications - Ju-Young Shin
College of Pharmacy, Seoul National University, Seoul, Republic of Korea
26 shared publications Joongyub Lee
Department of Prevention and Management, Inha University Hospital, Incheon, Korea
25 shared publicationsSun-Young Jung
Korea Institute of Drug Safety and Risk Management (KIDS), Boryung Bldg, 136 Changgyeonggung-ro, Jongno-Gu, Seoul 110-750, South Korea
11 shared publications- Joongyub Lee
Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
10 shared publications Seokyung Hahn
Medical Research Collaborating Center, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
10 shared publications
Latest Publications
- Open Access
- 30 September 2025
- Published by Korean Society of Evidence-Based Medicine in Journal of Evidence-Based Practice
- Vol. 1 (2) , 31-39
Development of evidence-based medicine and introduction to Korea
Evidence-Based Medicine (EBM) demands systematic changes across the healthcare system, essential for enhancing patient safety and quality of medical care. To address the question, "Are we adopting scientific methods to optimize patient safety and enhance treatment efficacy?", assessing the level of EBM implementation is crucial. The adoption rate of evidence-based medical practices varies across countries and medical fields, often being lower in resource-limited settings. In South Korea, there have been several documented cases where the adoption of non-evidence-based practices, such as CARVAR surgical procedures not based on scientific evidence, has led to severe patient safety issues, thereby raising significant concerns about the quality of medical care provided. Conversely, the ABBA Study exemplifies successful application of EBM, demonstrating how scientific research assessed the risk of intracranial hemorrhage in patients with low-dose PPA in OTC cold medicines. This study not only confirmed the associated risks but also influenced health policy, resulting in the withdrawal for PPA-containing OTC cold medicines in Korea. This positive example highlights the imperative for governments, healthcare institutions, and medical schools to expedite the transition to evidence-based, patient-centered healthcare by fostering a robust commitment to systematic reviews and enhanced support for clinical research. The Korean Society of Evidence-Based Medicine (KSEBM) is expected to play a significant role in embedding these core strategies domestically
- 30 September 2025
- Published by Korean Society of Evidence-Based Medicine in Journal of Evidence-Based Practice
- Vol. 1 (2) , 31-39
Open AccessDevelopment of evidence-based medicine and introduction to Korea
Evidence-Based Medicine (EBM) demands systematic changes across the healthcare system, essential for enhancing patient safety and quality of medical care. To address the question, "Are we adopting scientific methods to optimize patient safety and enhance treatment efficacy?", assessing the level of EBM implementation is crucial. The adoption rate of evidence-based medical practices varies across countries and medical fields, often being lower in resource-limited settings. In South Korea, there have been several documented cases where the adoption of non-evidence-based practices, such as CARVAR surgical procedures not based on scientific evidence, has led to severe patient safety issues, thereby raising significant concerns about the quality of medical care provided. Conversely, the ABBA Study exemplifies successful application of EBM, demonstrating how scientific research assessed the risk of intracranial hemorrhage in patients with low-dose PPA in OTC cold medicines. This study not only confirmed the associated risks but also influenced health policy, resulting in the withdrawal for PPA-containing OTC cold medicines in Korea. This positive example highlights the imperative for governments, healthcare institutions, and medical schools to expedite the transition to evidence-based, patient-centered healthcare by fostering a robust commitment to systematic reviews and enhanced support for clinical research. The Korean Society of Evidence-Based Medicine (KSEBM) is expected to play a significant role in embedding these core strategies domestically
- Open Access
- 25 July 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (7) , 746-754
Public Perception Towards Drug Abuse in South Korea: The Effects of Overconfidence and Affirmation
Objective The abuse of prescription drugs and over-the-counter medicines has been a major issue addressed as a serious public health problem worldwide. This study explored factors contributing to substance abuse in Korea by examining the status of substance abuse among Korean adults and evaluating their knowledge, attitudes, and intentions toward substance abuse.Methods Data were collected online from a sample of participants 19 years old or older from May 20 to June 1, 2020 (n=1,020). The survey consisted of questions on demographics, perceptions of drug risk, motives for drug use, and attitudes toward drug addiction treatment. Principal component and multiple logistic regression analyses were used to explore the factors contributing to the perception of drug abuse.Results In the multivariate regression analysis, overconfidence in handling drug usage, acceptance of addictive substances, and affirmation of public support for drug abuse were associated with opioid abuse (Nagelkerke R2=0.486), and additionally affirmation of legal cannabis usage and motivation to use diet pills were associated with diet pill abuse (Nagelkerke R2=0.569).Conclusion The findings of this study suggest that the actual situation of substance abuse among Korean adults increases awareness of and attitudes toward drug use related to substance abuse.
- 25 July 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (7) , 746-754
Open AccessPublic Perception Towards Drug Abuse in South Korea: The Effects of Overconfidence and Affirmation
Objective The abuse of prescription drugs and over-the-counter medicines has been a major issue addressed as a serious public health problem worldwide. This study explored factors contributing to substance abuse in Korea by examining the status of substance abuse among Korean adults and evaluating their knowledge, attitudes, and intentions toward substance abuse.Methods Data were collected online from a sample of participants 19 years old or older from May 20 to June 1, 2020 (n=1,020). The survey consisted of questions on demographics, perceptions of drug risk, motives for drug use, and attitudes toward drug addiction treatment. Principal component and multiple logistic regression analyses were used to explore the factors contributing to the perception of drug abuse.Results In the multivariate regression analysis, overconfidence in handling drug usage, acceptance of addictive substances, and affirmation of public support for drug abuse were associated with opioid abuse (Nagelkerke R2=0.486), and additionally affirmation of legal cannabis usage and motivation to use diet pills were associated with diet pill abuse (Nagelkerke R2=0.569).Conclusion The findings of this study suggest that the actual situation of substance abuse among Korean adults increases awareness of and attitudes toward drug use related to substance abuse.
- Open Access
- 30 April 2024
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 15 (2) , 97-106
The COVID-19 Vaccine Safety Research Center: a cornerstone for strengthening safety evidence for COVID-19 vaccination in the Republic of Korea
The COVID-19 Vaccine Safety Research Committee (CoVaSC) was established in November 2021 to address the growing need for independent, in-depth scientific evidence on adverse events (AEs) following coronavirus disease 2019 (COVID-19) vaccination. This initiative was requested by the Korea Disease Control and Prevention Agency and led by the National Academy of Medicine of Korea. In September 2022, the COVID-19 Vaccine Safety Research Center was established, strengthening CoVaSC’s initiatives. The center has conducted various studies on the safety of COVID-19 vaccines. During CoVaSC’s second research year, from September 29, 2022 to July 19, 2023, the center was restructured into 4 departments: Epidemiological Research, Clinical Research, Communication & Education, and International Cooperation & Policy Research. Its main activities include (1) managing CoVaSC and the COVID-19 Vaccine Safety Research Center, (2) surveying domestic and international trends in AE causality investigation, (3) assessing AEs following COVID-19 vaccination, (4) fostering international collaboration and policy research, and (5) organizing regular fora and training sessions for the public and clinicians. Causality assessments have been conducted for 27 diseases, and independent research has been conducted after organizing ad hoc committees comprising both epidemiologists and clinical experts on each AE of interest. The research process included protocol development, data analysis, interpretation of results, and causality assessment. These research outcomes have been shared transparently with the public and healthcare experts through various fora. The COVID-19 Vaccine Safety Research Center plans to continue strengthening and expanding its research activities to provide reliable, high-quality safety information to the public.
- 30 April 2024
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 15 (2) , 97-106
Open AccessThe COVID-19 Vaccine Safety Research Center: a cornerstone for strengthening safety evidence for COVID-19 vaccination in the Republic of Korea
The COVID-19 Vaccine Safety Research Committee (CoVaSC) was established in November 2021 to address the growing need for independent, in-depth scientific evidence on adverse events (AEs) following coronavirus disease 2019 (COVID-19) vaccination. This initiative was requested by the Korea Disease Control and Prevention Agency and led by the National Academy of Medicine of Korea. In September 2022, the COVID-19 Vaccine Safety Research Center was established, strengthening CoVaSC’s initiatives. The center has conducted various studies on the safety of COVID-19 vaccines. During CoVaSC’s second research year, from September 29, 2022 to July 19, 2023, the center was restructured into 4 departments: Epidemiological Research, Clinical Research, Communication & Education, and International Cooperation & Policy Research. Its main activities include (1) managing CoVaSC and the COVID-19 Vaccine Safety Research Center, (2) surveying domestic and international trends in AE causality investigation, (3) assessing AEs following COVID-19 vaccination, (4) fostering international collaboration and policy research, and (5) organizing regular fora and training sessions for the public and clinicians. Causality assessments have been conducted for 27 diseases, and independent research has been conducted after organizing ad hoc committees comprising both epidemiologists and clinical experts on each AE of interest. The research process included protocol development, data analysis, interpretation of results, and causality assessment. These research outcomes have been shared transparently with the public and healthcare experts through various fora. The COVID-19 Vaccine Safety Research Center plans to continue strengthening and expanding its research activities to provide reliable, high-quality safety information to the public.
- Open Access
- 30 April 2024
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 15 (2) , 107-114
Psychiatric adverse events associated with the COVID-19 vaccines approved in the Republic of Korea: a systematic review
This systematic review evaluated psychiatric adverse events (AEs) following vaccination against coronavirus disease 2019 (COVID-19). We included studies that reported or investigated psychiatric AEs in individuals who had received an approved COVID-19 vaccine in the Republic of Korea. Systematic electronic searches of Ovid-Medline, Embase, CENTRAL, and KoreaMed databases were conducted on March 22, 2023. Risk of bias was assessed using the Risk of Bias Assessment Tool for Non-randomized Studies 2.0. The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD42023449422). Of the 301 articles initially selected, 7 were included in the final analysis. All studies reported on sleep disturbances, and 2 highlighted anxiety-related AEs. Sleep disorders like insomnia and narcolepsy were the most prevalent AEs, while depression was not reported. Our review suggests that these AEs may have been influenced by biological mechanisms as well as the broader psychosocial context of the COVID-19 pandemic. Although this study had limitations, such as a primary focus on the BNT162b2 vaccine and an observational study design, it offered a systematic, multi-vaccine analysis that fills a critical gap in the existing literature. This review underscores the need for continued surveillance of psychiatric AEs and guides future research to investigate underlying mechanisms, identify risk factors, and inform clinical management.
- 30 April 2024
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 15 (2) , 107-114
Open AccessPsychiatric adverse events associated with the COVID-19 vaccines approved in the Republic of Korea: a systematic review
This systematic review evaluated psychiatric adverse events (AEs) following vaccination against coronavirus disease 2019 (COVID-19). We included studies that reported or investigated psychiatric AEs in individuals who had received an approved COVID-19 vaccine in the Republic of Korea. Systematic electronic searches of Ovid-Medline, Embase, CENTRAL, and KoreaMed databases were conducted on March 22, 2023. Risk of bias was assessed using the Risk of Bias Assessment Tool for Non-randomized Studies 2.0. The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD42023449422). Of the 301 articles initially selected, 7 were included in the final analysis. All studies reported on sleep disturbances, and 2 highlighted anxiety-related AEs. Sleep disorders like insomnia and narcolepsy were the most prevalent AEs, while depression was not reported. Our review suggests that these AEs may have been influenced by biological mechanisms as well as the broader psychosocial context of the COVID-19 pandemic. Although this study had limitations, such as a primary focus on the BNT162b2 vaccine and an observational study design, it offered a systematic, multi-vaccine analysis that fills a critical gap in the existing literature. This review underscores the need for continued surveillance of psychiatric AEs and guides future research to investigate underlying mechanisms, identify risk factors, and inform clinical management.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (26) , e220
A Causality Assessment Framework for COVID-19 Vaccines and Adverse Events at the COVID-19 Vaccine Safety Research Center
Kim S, et al. J Korean Med Sci. 2024 Jul;39(26):e220. https://doi.org/10.3346/jkms.2024.39.e220
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (26) , e220
Open AccessA Causality Assessment Framework for COVID-19 Vaccines and Adverse Events at the COVID-19 Vaccine Safety Research Center
Kim S, et al. J Korean Med Sci. 2024 Jul;39(26):e220. https://doi.org/10.3346/jkms.2024.39.e220
- Open Access
- 25 July 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (7) , 671-680
Social Stigma and Discrimination Toward People With Drug Addiction: A National Survey in Korea
Objective This study aims to understand the attitudes, stigma, and discrimination of the general adult population toward drug addiction.Methods We conducted a cross-sectional nationwide survey with 1,020 Korean adults using an Internet web-based panel. Self-reported data were collected on demographics, experience with substance abuse, perceptions of narcotic analgesic use, beliefs about the legalization of cannabis use, coping with substance abuse and addiction, and perceptions of drug risks. All statistical analysis in this study utilized the IBM SPSS Statistics 26 program.Results In this study, 1.6% of the participants reported abuse of opioid analgesics, 88.0% reported negative perceptions of drug addiction, and 76.9% reported agreeing to unfair treatment of drug addicts. Logistic regression analysis found that perceived stigma was more prevalent among women (odd ratio [OR]=2.087, p<0.01), old adults (OR=1.939, p<0.01), those with no personal experience of opioid misuse (OR=8.172, p<0.05), and those who were non-smoking (OR=2.011, p<0.01). In addition, the discriminatory attitude was more prevalent among participants with higher income (OR=1.989, p<0.001) and those who are non-smoking (OR=1.608, p<0.05).Conclusion This study provides information and guidelines for public intervention in drug addiction by identifying factors influencing social stigma and discriminatory behaviors toward drug addiction. The findings suggest that education on drug addiction prevention for the general adult population is necessary, and this education should include knowledge on coping with drug addiction and reducing stigma and discrimination toward drug addicts.
- 25 July 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (7) , 671-680
Open AccessSocial Stigma and Discrimination Toward People With Drug Addiction: A National Survey in Korea
Objective This study aims to understand the attitudes, stigma, and discrimination of the general adult population toward drug addiction.Methods We conducted a cross-sectional nationwide survey with 1,020 Korean adults using an Internet web-based panel. Self-reported data were collected on demographics, experience with substance abuse, perceptions of narcotic analgesic use, beliefs about the legalization of cannabis use, coping with substance abuse and addiction, and perceptions of drug risks. All statistical analysis in this study utilized the IBM SPSS Statistics 26 program.Results In this study, 1.6% of the participants reported abuse of opioid analgesics, 88.0% reported negative perceptions of drug addiction, and 76.9% reported agreeing to unfair treatment of drug addicts. Logistic regression analysis found that perceived stigma was more prevalent among women (odd ratio [OR]=2.087, p<0.01), old adults (OR=1.939, p<0.01), those with no personal experience of opioid misuse (OR=8.172, p<0.05), and those who were non-smoking (OR=2.011, p<0.01). In addition, the discriminatory attitude was more prevalent among participants with higher income (OR=1.989, p<0.001) and those who are non-smoking (OR=1.608, p<0.05).Conclusion This study provides information and guidelines for public intervention in drug addiction by identifying factors influencing social stigma and discriminatory behaviors toward drug addiction. The findings suggest that education on drug addiction prevention for the general adult population is necessary, and this education should include knowledge on coping with drug addiction and reducing stigma and discrimination toward drug addicts.
- Open Access
- 28 February 2023
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 14 (1) , 5-14
A framework for nationwide COVID-19 vaccine safety research in the Republic of Korea: the COVID-19 Vaccine Safety Research Committee
With the introduction of coronavirus disease 2019 (COVID-19) vaccines, the Korea Disease Control and Prevention Agency (KDCA) commissioned the National Academy of Medicine of Korea to gather experts to independently assess post-vaccination adverse events. Accordingly, the COVID-19 Vaccine Safety Research Committee (CoVaSC) was launched in November 2021 to perform safety studies and establish evidence for policy guidance. The CoVaSC established 3 committees for epidemiology, clinical research, and communication. The CoVaSC mainly utilizes pseudonymized data linking KDCA’s COVID-19 vaccination data and the National Health Insurance Service’s claims data. The CoVaSC’s 5-step research process involves defining the target diseases and organizing ad-hoc committees, developing research protocols, performing analyses, assessing causal relationships, and announcing research findings and utilizing them to guide compensation policies. As of 2022, the CoVaSC completed this research process for 15 adverse events. The CoVaSC launched the COVID-19 Vaccine Safety Research Center in September 2022 and has been reorganized into 4 divisions to promote research including international collaborative studies, long-/short-term follow-up studies, and education programs. Through these enhancements, the CoVaSC will continue to swiftly provide scientific evidence for COVID-19 vaccine research and compensation and may serve as a model for preparing for future epidemics of new diseases.
- 28 February 2023
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 14 (1) , 5-14
Open AccessA framework for nationwide COVID-19 vaccine safety research in the Republic of Korea: the COVID-19 Vaccine Safety Research Committee
With the introduction of coronavirus disease 2019 (COVID-19) vaccines, the Korea Disease Control and Prevention Agency (KDCA) commissioned the National Academy of Medicine of Korea to gather experts to independently assess post-vaccination adverse events. Accordingly, the COVID-19 Vaccine Safety Research Committee (CoVaSC) was launched in November 2021 to perform safety studies and establish evidence for policy guidance. The CoVaSC established 3 committees for epidemiology, clinical research, and communication. The CoVaSC mainly utilizes pseudonymized data linking KDCA’s COVID-19 vaccination data and the National Health Insurance Service’s claims data. The CoVaSC’s 5-step research process involves defining the target diseases and organizing ad-hoc committees, developing research protocols, performing analyses, assessing causal relationships, and announcing research findings and utilizing them to guide compensation policies. As of 2022, the CoVaSC completed this research process for 15 adverse events. The CoVaSC launched the COVID-19 Vaccine Safety Research Center in September 2022 and has been reorganized into 4 divisions to promote research including international collaborative studies, long-/short-term follow-up studies, and education programs. Through these enhancements, the CoVaSC will continue to swiftly provide scientific evidence for COVID-19 vaccine research and compensation and may serve as a model for preparing for future epidemics of new diseases.
- Open Access
- 20 May 2022
- Published by XMLink in Journal of Clinical Neurology
- Vol. 18 (5) , 547-552
Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy
Kim SH, et al. J Clin Neurol. 2022 Sep;18(5):547-552. https://doi.org/10.3988/jcn.2022.18.5.547
- 20 May 2022
- Published by XMLink in Journal of Clinical Neurology
- Vol. 18 (5) , 547-552
Open AccessEffects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy
Kim SH, et al. J Clin Neurol. 2022 Sep;18(5):547-552. https://doi.org/10.3988/jcn.2022.18.5.547
- 1 April 2021
- Published by Elsevier in Psychiatry Research
- Vol. 298, 113744
Comparison of risk of cardiovascular disease related adverse events between selective serotonin reuptake inhibitor users and serotonin norepinephrine reuptake inhibitor users in Korean adult patients with depression: retrospective cohort study.
- 1 April 2021
- Published by Elsevier in Psychiatry Research
- Vol. 298, 113744
Comparison of risk of cardiovascular disease related adverse events between selective serotonin reuptake inhibitor users and serotonin norepinephrine reuptake inhibitor users in Korean adult patients with depression: retrospective cohort study.
- 9 July 2020
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 40 (9) , 873-881
Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database
Background and Objectives Schizophrenia is a severe public health problem and one of the top ten causes of disability, affecting about 1.1% of the world’s population. Paliperidone is a new atypical antipsychotic used to treat schizophrenia. Several case reports about unexpected adverse drug reactions of paliperidone have been consistently reported around the world. The purpose of this study was to detect signals of adverse events (AEs) after paliperidone treatment using the Korea Institute of Drug Safety and Risk Management–Korea Adverse Event Reporting System database (KIDS-KD). Methods We applied data-mining techniques based on a disproportionality analysis to KIDS-KD consisting of spontaneously reported AE reports related to atypical antipsychotics between January 2009 and December 2018. We calculated three data-mining indices of paliperidone compared to all other atypical antipsychotics. We defined signals that satisfied all three criteria of the indices. We checked if the signals identified were included in the drug labels for South Korea, the USA, the UK, Japan, Germany, and France. Results The total number of suspected AE reports related to all atypical antipsychotics in the KIDS-KD from January 2009 to December 2018 was 43,970. Among those, the number of AE reports related to paliperidone was 9453. Overall, 13 signals such as seborrhea, hallucination, obesity, gingivitis, and intervertebral disorder were classified into newly detected meaningful signals. Conclusion We detected new AE signals of paliperidone that were not listed on the drug labels of six countries, and many that were related to psychotic symptoms, metabolic problems, and endocrine disorders.
- 9 July 2020
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 40 (9) , 873-881
Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database
Background and Objectives Schizophrenia is a severe public health problem and one of the top ten causes of disability, affecting about 1.1% of the world’s population. Paliperidone is a new atypical antipsychotic used to treat schizophrenia. Several case reports about unexpected adverse drug reactions of paliperidone have been consistently reported around the world. The purpose of this study was to detect signals of adverse events (AEs) after paliperidone treatment using the Korea Institute of Drug Safety and Risk Management–Korea Adverse Event Reporting System database (KIDS-KD). Methods We applied data-mining techniques based on a disproportionality analysis to KIDS-KD consisting of spontaneously reported AE reports related to atypical antipsychotics between January 2009 and December 2018. We calculated three data-mining indices of paliperidone compared to all other atypical antipsychotics. We defined signals that satisfied all three criteria of the indices. We checked if the signals identified were included in the drug labels for South Korea, the USA, the UK, Japan, Germany, and France. Results The total number of suspected AE reports related to all atypical antipsychotics in the KIDS-KD from January 2009 to December 2018 was 43,970. Among those, the number of AE reports related to paliperidone was 9453. Overall, 13 signals such as seborrhea, hallucination, obesity, gingivitis, and intervertebral disorder were classified into newly detected meaningful signals. Conclusion We detected new AE signals of paliperidone that were not listed on the drug labels of six countries, and many that were related to psychotic symptoms, metabolic problems, and endocrine disorders.